Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DREAMM-11: Belantamab mafodotin in Japanese participants with relapsed/refractory multiple myeloma
jRCT2080224530Phase 1Completed
- Sponsor
- GSK
- Start
- Jan 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of belantamab mafodotin in multiple myeloma (MM) (3 arms), sponsored by GSK. Primary endpoints: Dose-limiting toxicities (DLTs), Safety and tolerability and 1 more. Started Jan 2019; status: completed.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2080224530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224530.